rais fve narrow-moat iqvia due robust
updat forecast estim may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data may
rate updat may
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
iqvia formerli quintilesim result merger
quintil lead late-stag contract research organ
im health domin player life scienc data analyt
long-term strateg benefit merger remain somewhat
uncertain question compani
entrench leader cro space life scienc data
analyt result merger compani lead
real-world evid data sourc patient
record medic claim use creat clinic evid
regulatori approv
revenu come research
develop segment outsourc clinic research
technolog analyt segment legaci im health
real-world data solut contract sale
research develop segment focus late-stag
research requir thousand patient across globe
iqvia one global infrastructur win
contract size mean work clinic trial
competitor sharpen clinic regulatori
compani comprehens data set de-identifi patient
record script data enhanc abil attract retain
healthcar custom throughout life cycl drug product
iqvia compil data sourc includ
pharmaci medic claim electron health record
access million patient record unmatch data
set layer proprietari methodolog enabl client set
inform strategi effect commerci drug
result busi command price premium high
retent rate exist client access data help inform
patient identif clinic trial success trial design
true advantag lie real-world evid
cohort de-identifi patient data set use lieu
tradit clinic trial cohort regulatori approv
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
iqvia result merger quintil lead global contract
research organ im health lead healthcar data
analyt provid cro segment focus primarili provid
outsourc late-stag clinic trial pharmaceut devic
technolog servic client healthcar industri includ
pharmaceut compani provid payer policymak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rais fair valu estim per share
adjust near-term revenu outlook
technolog analyt segment perform
ahead expect fair valu estim driven
mid- high-single-digit top-lin growth oper
margin improv continu tuck-in acquisit
impli enterpris valu time adjust
ebitda forward price-to-earnings ratio time
expect cro industri grow midsingl digit
due low-single-digit growth biopharma research
develop spend well modest increas
outsourc penetr believ iqvia gain
share cro space research develop
segment grow slightli higher clip industri
rate billion revenu
believ technolog analyt segment
grow faster rate life scienc data analyt play
larger role clinic trial mission-crit
process biopharma industri model
five-year revenu compound-annual-growth-rate
billion revenu expect small contract
sale segment return single-digit growth
see opportun margin improv
research develop segment model ebitda
margin improv basi point
expect iqvia push fixed-pric contract contract
visibl cost allow retain
higher margin think room margin
expans technolog analyt segment
throughout explicit forecast model basi
point ebitda margin improv addit
autom help reduc cost expect mix play
role well growth higher-margin real-world
evid trial use de-identifi patient data cohort
evid regulatori approv
model long-term effect tax rate believ
firm continu grow acquir smaller cro
relat technolog compani model continu
tuck-in acquisit assum mid-cycle
capit expenditur sale
believ iqvia medium uncertainti rate due
vulner biopharma research develop
spend outsourc level well potenti
competit data analyt space
market either due slowdown global spend
biopharma industri hit macroeconom
headwind declin outsourc penetr
biopharma bring clinic trial process hous
competitor veeva gain share life
scienc data space case revenu
billion case cost expand due high salari
need retain talent oper margin
year forecast result
bear-cas fair valu estim per share
bull case assum iqvia address market
expand due faster-than-expect growth research
develop spend higher level outsourc
quick uptak real-world evid trial iqvia
abl effect differenti data analyt
offer competitor case firm earn
billion revenu case assum iqvia
improv gross oper margin util
capac effici abl adapt better
trial cancel result mid-cycle oper
margin bull-cas fair valu estim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
evid trial data sourc patient
record medic claim use creat clinic
increas import data analyt cro
space believ iqvia signific cro market
share unparallel data capabl best posit
lead way real-world evid work compar
peer largest cro iqvia abil
influenc industri trend includ move data
analyt follow im health quintil merger
sever began build data capabl
acquisit partnership albeit lesser degre
real-world data trend earli day view
recent rhetor food drug administr
includ set guidelin decemb
posit indic potenti real-world evid
firm cro busi moatworthi right
infrastructur diversifi client base
late-stag exposur believ exposur late-stag
clinic trial crucial moat cro space
late-stag trial larger scope complex often
multi-national higher risk failur
differenti global leverag expertis
shorten clinic trial time frame ensur accuraci
precis iqvia maintain top spot cro market
share cro revenu come late-stag
work firm diversifi client base split
small/mids custom
larger biotech
pharmaceut compani broad portfolio
commerci believ diversifi client base
strengthen iqvia competit advantag small/mids
client like need full outsourc solut
partnership high switch cost choos one
trust funnel new
central
iqvia leader clinic research healthcar data
nearli everi major biotechnolog pharmaceut
compani pay
proprietari data clinic develop expertis
posit firm well closest peer
intang asset high switch cost underpin
servic think
iqvia result merger im health
lead data analyt compani life scienc
quintil global cro largest market share
strateg advantag merger initi clear
im health provid data biotechnolog
pharmaceut compani rather lack
cro demand im health capabl littl
overlap two firm threw question whether
firm would abl achiev synergi whether
integr would smooth view data
analyt capabl im health posit advantag
iqvia util vast patient data inform clinic trial
plan execut recent interest real-world
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
evid strategi sourc patient record
medic claim provid data regulatori approv
fda biopharma industri voic need
modern clinic trial process heavili
reli technolog believ difficulti obtain
extens databas develop best-in-class
technolog creat high barrier entri believ
grow market support smaller competitor
symphoni veeva without endang iqvia narrow
moat would consid upgrad posit moat trend
rate signific polici come fda
would make real-world evid preval
entrench iqvia data technolog advantag
would consid downgrad neg moat trend rate
shift data privaci regul interoper
initi lower barrier entri make easier
competitor encroach compani lead patient
iqvia data analyt busi also deserv moat
due intang asset switch cost
proprietari data set sourc sourc
pharmaci claim registri patient record
scale data best-in-class analyt
technolog iqvia layer data creat high barrier
entri closest competitor iqvia technolog side
symphoni health offer smaller portfolio
data servic much smaller market share
veeva compet iqvia client relationship
manag increasingli data analyt
veeva captur signific share life scienc
cloud servic space believ iqvia reput
asset data space unparallel evidenc
retent rate top client
biotech pharmaceut client use iqvia servic
mission-crit function plan new product
launch forecast revenu market sell
client like continu choos trust iqvia data
believ iqvia stabl moat trend competit
dynam cro data space fundament
shift compani strategi consult
technolog aspect busi grow import
iqvia remain well posit space due
expans intang asset opinion believ
firm continu hold top share cro space due
exposur late-stag trial breadth
expertis complex diseas area diversifi client
base recent book backlog metric indic
cro industri continu grow
percentag outsourc grow slowli
data space iqvia advantag util
vast proprietari data capabl inform real-world
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oiqvia lead posit outsourc clinic trial
allow creat sticki client relationship
hone clinic regulatori expertis
traction among client fail gain traction
oth merger im health provid access
unparallel databas patient data
strengthen clinic trial offer
oth on-going shift outsourc provid
cro industri steadi growth regardless
trend global research develop spend
oiqvia contract sale segment larg no-moat
busi lack competit advantag
ochang data privaci regul could
make easier competitor gain access de-
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
iqvia decent financi health strong cash flow
gener clinic research technolog
busi assuag concern larg debt
load merger end compani
billion total gross debt debt time
adjust ebitda firm million cash
balanc sheet expect gener
billion oper cash flow expect healthi
cash gener clinic research
technolog segment concern
compani meet debt oblig matur
iqvia long-term debt
floating-r debt expect compani alloc
capit share buyback smaller acquisit
throughout explicit forecast period
cro industri highli depend spend
outsourc prefer custom base biotech
pharmaceut compani believ
decreas spend outsourc like
near term left expos risk
biopharma fund constrain chang
drug approv regulatori landscap biopharma
industri face macroeconom headwind iqvia
largest player cro space well-diversifi
revenu base singl client make
sale result think compani well
diversifi client concentr
risk
individu trial cancel sizabl impact
cro busi result compani also suscept
shift clinic trial data privaci regul
leader real-world evid iqvia success
highli depend regulatori cooper real-world
evid offer worth premium
complet embrac fda regulatori
entiti compani oper depend heavili
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
use de-identifi patient data technolog
analyt segment well research develop
segment chang privaci guidelin could affect
suppli use data make easier competitor
amass patient data
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
chairman board/president/
repres date owner name posit common share held report holder issuer
leadership team appropri experi span
consult clinic research healthcar data
analyt quintil im health merger
strateg bet futur data analyt
clinic research space note transact
significantli decreas level adjust return
invest capit roic believ one
import measur sharehold valu prior
merger quintil busi enjoy sky-high return
invest capit care execut manag
believ roic increas steadili compani
integr continu watch iqvia
leverag im data analyt asset
merger late bousbib former im
health ceo board chairman took posit
combin compani bousbib led im health sinc
hold sever leadership role unit
technolog think compani capit alloc
rel shareholder-friendli leadership
merger former quintil ceo thoma pike serv
vice chairman presid solut
retir compani coupl month later
pike earli departur rais eyebrow think cro
busi remain steadi hand leadership
 richard staub join quintil
acquisit specialti cro novella clinic
technolog segment led kevin knightli work
im year jon resnick presid
real-world analyt solut work im
share
fund
share
fund
fidel manag research compani
prefer see chairman ceo role
separ remaind board made
independ director director
design privat equiti sharehold tpg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
design two director own outstand
share februari one director design
canada pension invest board
bain capit leonard green partner
tpg cppib leonard green took im privat
presenc privat equiti uncommon
cro industri mani top global player previous
restructur current firm period privat
equiti ownership believ owner interest
align minor sharehold note could
deviat long term denni gill found
quintil own share retir
board director april
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
narrow-moat iqvia report robust top-lin growth
contract research organ iqvia start year well
billion revenu slightli surpass
expect repres growth constant
currenc report despit currenc headwind
termin major trial manag maintain
full-year guidanc affirm oper
environ clinic develop servic remain
strong adjust near-term revenu outlook
technolog analyt segment perform
ahead expect anticip low- mid-
single-digit increas fair valu estim strong
research
develop segment support intang
asset switch cost underpin compani
technolog
technolog analyt segment post billion
revenu nearli constant currenc
report call manag point
one third technolog segment legaci im data
busi grow leav real-world evid
iqvia custom relationship manag platform
name oce drive segment double-digit growth
sale product servic acceler
quicker expect result organ growth
technolog segment quarter compar
histor level
research develop segment contribut
billion revenu quarter constant currenc
report backlog grew billion
adjust million termin major late-
stage alzheim trial even without adjust
cancel trial quarterli backlog growth seem
slow slightli sequenti basi said
adjust backlog growth trail basi
remain healthi compani anticip
billion convert revenu next
oper expens line expect
believ compani track improv oper
margin basi point free cash flow
weaker expect quarter neg
million due annual incent payment employe
higher capit expenditur headwind time
reimburs associ compani loyalti
program increas near-term capit expenditur
expect iqvia continu invest technolog
offer expect free cash flow normal
remaind year iqvia remain highli leverag
billion debt net leverag ratio time
gener clinic research
technolog segment concern
compani meet debt oblig
iqvia report anoth solid quarter like
narrow-moat busi share remain overvalu
anticip materi chang fair valu
estim narrow-moat iqvia report fourth-
quarter earn revenu earn came slightli
analyst expect fourth-quart
revenu nearli billion repres year-over-
year growth constant currenc top-lin growth
driven solid result technolog analyt nearli
constant currenc slightli expect
research develop constant
currenc line expect contract
sale segment continu declin expect
manag guidanc slightli lower
expect top line still comfort
long-term forecast mid- high-single-digit revenu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
technolog analyt solut post
billion revenu fourth quarter driven demand
constantli chang portfolio commerci offer
includ oce platform
relationship manag market well double-
digit growth real-world evid offer manag
note compani work number
single-arm trial hybrid tradit clinic
trial use real-world data compar arm iqvia
abil leverag unmatch data asset drug
develop one pillar support compani narrow
moat expect iqvia maintain lead posit
emerg space real-world evid
research develop solut contribut
billion fourth-quart revenu pleas
see strong book growth last year
bring total backlog billion includ zero-
margin reimburs expens growth rate
book acceler throughout year
attribut robust oper environ
strong biotech fund continu biopharma drug
innov well compani sale effort
merger manag note rfp volum
increas expect momentum
continu
interestingli manag said expect
contract sale segment return growth fiscal
issu guidanc nearli flat full-year revenu
segment howev contract sale repres less
revenu believ busi
add much iqvia competit advantag
entir clear drive expect improv
segment expect like combin
favor oper environ better leverag
segment may adjust forecast segment
clariti manag
materi impact valuat
state earlier plan make
chang long-term outlook iqvia expect
expect revenu growth increment margin
improv fiscal like mark
continu invest oce relat technolog
offer real-world evid sale effort
cro pois benefit biopharma outsourc
transfer coverag major late-stag contract
research organ thesi industri
remain continu outsourc biotechnolog
pharmaceut compani drive growth larger
global help design conduct clinic trial
maintain narrow moat stabl trend rate
syneo health icon downgrad
market leader iqvia moat narrow wide
posit clinic research data space
four narrow-moat syneo look
attract territori note
high uncertainti rate due high
debt load merger inc research
compani
iqvia moat downgrad lower fair valu
estim continu view share
fairli valu believ intang asset
switch cost underpin narrow econom moat
iqvia longer confid firm earn
excess return least year compani return
invest capit significantli diminish follow
merger quintil im health
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
improv note compani slightli
higher exposur lower-margin staf solut
peer expect manag roll plan
integr symphoni data clinic research
high confid firm maintain
monopolist hold aggreg patient data
decad contract research organ softwar
compani increasingli engag patient data
begin play increas role clinic research
commerci believ
technolog interoper could eventu lower
barrier access patient data
maintain fair valu estim per share
syneo health result merger inc
research inventiv health lacklust growth
quarter follow merger due
cancel commerci segment final stabil
like compani focu integr deal
drive revenu clinic commerci
busi howev compani took signific debt
merger could constrain capit alloc
strategi near term expect syneo complet
fiscal total debt time adjust
ebitda debt matur push
beyond
rais icon fair valu estim
per share due slightli higher growth expect
near term expect icon continu diversifi
revenu base away client concentr risk
top client maintain focu lucr
partnership larg biopharma client share remain
overvalu
acquisit strategi solid execut evidenc
higher oper margin higher adjust return
invest capit compar peer
lower health fair valu estim
per share re-examin long-term cost
assumpt view share fairli valu still
model robust top-lin growth continu margin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
